Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBunzl Regulatory News (BNZL)

Share Price Information for Bunzl (BNZL)

Share Price is delayed by 15 minutes
Get Live Data
2,422.00    32.00 (1.34%)
Bid:
2,420.00
Ask:
2,424.00
Spread: 4.00 (0.165%)
Market Cap: £7.78b
BNZL Live PriceLast checked at - London Stock Exchange

Intraday Bunzl Share Chart

Trading Statement

24 Oct 2024 07:00

RNS Number : 3430J
Bunzl PLC
24 October 2024
 

24 October 2024

BUNZL Q3 TRADING STATEMENT

IMPROVED UNDERLYING REVENUE GROWTH; FY GUIDANCE UNCHANGED

 

Bunzl plc, the specialist international distribution and services Group, today announces its trading statement for the period since 30 June 2024.

Group revenue in the quarter grew by 5.4% at constant exchange rates. Underlying revenue, which is organic revenue adjusted for trading days1declined by 1.2%, an expected improvement in trading compared to the prior quarter as underlying revenue trends continue to strengthen. Improved performance through the quarter in our US foodservice redistribution business supported volume growth in North America, with the Group overall delivering modest volume growth year-on-year. Acquisitions contributed growth of 6.8% at constant exchange rates. Overall, at actual exchange rates, Group revenue grew by 2.0%. Operating margin over the quarter was in line with expectations, supporting our 2024 outlook.

The Group's full year guidance remains unchanged. The Group continues to expect to deliver robust revenue growth, at constant exchange rates, driven by acquisitions already completed in 2024; with a small decline in underlying revenue. We continue to expect adjusted operating profit in 2024 to show a strong increase in comparison with 2023, at constant exchange rates, with Group operating margin expected to be moderately above the level reported for 2023.

In August 2024, we made a commitment to allocate c.£700 million per annum, primarily to be invested in value-accretive acquisitions and, if required, returns of capital in each of the three years ending 31 December 2027, which is intended to steadily return Bunzl to its target leverage range by the end of 2027. We also initiated a £250 million buyback with immediate effect with an expectation of announcing a further buyback at our 2024 preliminary results. Since the results we have executed approximately £100 million of the £250 million buyback, and as set out below, continued to invest in value-accretive acquisitions.

In August, Bunzl completed the acquisition of Cermerón, a regional distributor of cleaning & hygiene products to foodservice and hospitality customers in Southern Spain, which enhances Bunzl's regional strength in these sectors. The business generated revenue of EUR 13 million (£11 million) in 2023.

In September, Bunzl completed the acquisition of Cubro Group ("Cubro"), the leading distributor of mobility aids and clinical furniture to the aged care, community care, and hospital markets in New Zealand. This fast-growing business expands our offering in the healthcare market, and generated NZD 92 million (£44 million) of revenue in the year to March 2024.

In September, Bunzl completed the acquisition of DBM Medical Group ("DBM"), a specialist distributor of orthopaedic surgery products in New Zealand. DBM complements our growing healthcare business in the region and generated NZD 16 million (£7 million) of revenue in the year to June 2024.

In October, Bunzl completed the acquisition of Arrow County Holdings Limited ("Arrow"), a distributor of cleaning and hygiene products in the UK, with a strong own brand portfolio. The business complements our existing customer offering and generated revenue of £24 million in 2023.

Commenting on today's announcement, Frank van Zanten, Chief Executive Officer of Bunzl, said:

 

"Bunzl has delivered another period of good growth that demonstrates the ongoing strength of our compounding strategy and resilient business model. I am pleased to see continued momentum in underlying revenue performance and the extension of this year's acquisition success, with 11 acquisitions announced, and our pipeline remaining active. We welcome Cubro, DBM, Cermerón and Arrow, strengthening our growing position in New Zealand's healthcare market, enhancing our regional position in Spain, and complementing our own brand portfolio in the UK. Our initial £250 million share buyback is also well underway, and I reiterate our commitment to allocate c.£700 million per annum, primarily to invest in value-accretive acquisitions and, if required, returns of capital in each of the three years to 2027."

Enquiries:

 

Bunzl plc

Frank van Zanten, Chief Executive Officer

Richard Howes, Chief Financial Officer

Sunita Entwisle, Head of Investor Relations and Communications

Tel: +44 (0)20 7725 5000

Teneo

Martin Robinson

Olivia Peters

Tel: +44 (0)20 7353 4200

1. Net of the benefit of growth in excess of 26% per annum in hyperinflationary economies, which contributed a small decrease of 0.2%. Trading days had a negligible impact over the period.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTBXBDGLGDDGSX
Date   Source Headline
18th Apr 20248:00 amRNSAdditional Listing
11th Apr 20248:00 amRNSAdditional Listing
3rd Apr 20245:28 pmRNSDirector/PDMR Shareholding
3rd Apr 20249:09 amRNSDirector/PDMR Shareholding
2nd Apr 20241:50 pmRNSTotal Voting Rights
21st Mar 20248:00 amRNSAdditional Listing
15th Mar 20243:28 pmRNSAnnual Financial Report
7th Mar 20248:00 amRNSAdditional Listing
5th Mar 20245:05 pmRNSDirector/PDMR Shareholding
4th Mar 20243:03 pmRNSDirector/PDMR Shareholding
1st Mar 202411:35 amRNSTotal Voting Rights
28th Feb 20243:17 pmRNSDirector/PDMR Shareholding
27th Feb 20245:26 pmRNSDirector/PDMR Shareholding
26th Feb 202410:30 amRNSDividend Declaration
26th Feb 20247:00 amRNSFinal Results
26th Feb 20247:00 amRNSAcquisition
5th Feb 20242:20 pmRNSDirector/PDMR Shareholding
1st Feb 20245:08 pmRNSTotal Voting Rights
12th Jan 20244:54 pmRNSDirector/PDMR Shareholding
11th Jan 20243:50 pmRNSDirector/PDMR Shareholding
2nd Jan 202410:57 amRNSTotal Voting Rights
15th Dec 20235:10 pmRNSHolding(s) in Company
14th Dec 20237:00 amRNSTrading Statement
8th Dec 20235:32 pmRNSDirector/PDMR Shareholding
1st Dec 202311:32 amRNSTotal Voting Rights
20th Nov 20236:30 pmRNSPublication of Admission Particulars
3rd Nov 20239:30 amRNSDirector Declaration
2nd Nov 20232:29 pmRNSDirector/PDMR Shareholding
1st Nov 202311:24 amRNSTotal Voting Rights
1st Nov 20239:00 amRNSBlock listing Interim Review
24th Oct 20237:00 amRNSTrading Statement
6th Oct 20235:08 pmRNSDirector/PDMR Shareholding
4th Oct 20231:40 pmRNSDirector/PDMR Shareholding
2nd Oct 20231:34 pmRNSTotal Voting Rights
2nd Oct 20231:33 pmRNSDirector/PDMR Shareholding
26th Sep 20232:10 pmRNSDirector/PDMR Shareholding
1st Sep 20232:30 pmRNSTotal Voting Rights
31st Aug 202310:30 amRNSDirector/PDMR Shareholding
29th Aug 202310:00 amRNSDividend Declaration
29th Aug 20237:00 amRNSHalf-year Report
29th Aug 20237:00 amRNSAcquisition
15th Aug 20237:00 amRNSAcquisition
2nd Aug 20233:45 pmRNSDirector/PDMR Shareholding
1st Aug 202311:17 amRNSTotal Voting Rights
13th Jul 20234:20 pmRNSDirector/PDMR Shareholding
13th Jul 20237:00 amRNSOutcome of audit tender process
11th Jul 20234:50 pmRNSDirector/PDMR Shareholding
6th Jul 202310:44 amRNSDirector/PDMR Shareholding
3rd Jul 20234:45 pmRNSTotal Voting Rights
29th Jun 20233:26 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.